In order to address the potential role of the RANKL pathway in another primary bone tumor, this study assessed human RANKL and RANK expression in human primary osteosarcoma (OS) using specific mAbs, validated and optimized for immunohistochemistry (IHC) or flow cytometry.

RANKL (also known as TRANCE) is a homotrimeric transmembrane protein member of the tumor necrosis factor (TNF) cytokine family, initially identified as a mediator of T cell-dependent immune response, particularly in the modulation of T cell [11] and dendritic cell (DC) activity [12].

2021年4月1日 · In this study, we found that RANK expression was markedly upregulated in CRC tissues compared with that in matched noncancerous tissues. Increased RANK expression correlated positively with...

2020年12月10日 · Increased CD3 + T-lymphocyte and CD8 + T-cell tumor infiltration in RANK −/− tumors compared with RANK +/+ was confirmed by IHC (Fig. 2b, c) and the mRNA levels of the cytotoxicity markers ...

2024年6月20日 · RANKL/RANK signaling promotes tumor growth by influencing multiple downstream pathways, including tumor metabolism, treatment resistance, and tumor immunity. RANKL has been linked to an...

In this study, we examined the expression of RANKL and RANK by immunohistochemistry (IHC) staining in tumor samples from 116 GC patients who underwent surgical treatment. The correlation between RANKL and RANK and their association with the clinicopathological characteristics and overall survival (OS) were also evaluated.

GCTB is composed of osteoclast-like giant cells and myeloid giant cell precursors that express RANK and stromal tumor cells that express RANKL. (A) The RANKL IHC using M366 clearly indicates...

2015年2月21日 · Receptor activator for nuclear factor κB ligand (RANKL) is a key factor in bone resorption. It binds to receptor activator for nuclear factor κB (RANK) on the osteoclast to promote osteoclastogenesis, which results in bone destruction, osteoporosis and osseous metastasis [1].

2015年5月1日 · Here, we report for the first time the expression of RANK/RANKL in young BC patients using IHC, and its association with diagnosis during pregnancy and prognosis. We also evaluate genes and pathways that are activated in RANK/RANKL expressing tumors. Patients & Methods: 195 young BC patients were included; of whom 65 were diagnosed during ...